Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2017-01-16
|
fruquintinib |
non-small cell lung cancer (NSCLC) |
2 |
Hutchison China MediTech Limited "ChiMed" (China) |
Cancer - Oncology |
2017-01-13
|
cenicriviroc (CVC) |
liver fibrosis in adult subjects with NASH |
3 |
Tobira Therapeutics (USA - CA), now Allergan (Ireland) |
Hepatic diseases - Liver diseases |
2017-01-13
|
Spinraza™ -nusinersen - ISIS-SMNRx (antisense oligonucleotide targeted to the SMN2 gene) |
spinal muscular atrophy |
3 |
Ionis Pharmaceuticals (USA - CA) |
Neuromuscular diseases - Rare diseases - Genetic diseases |
2017-01-12
|
PLX-PAD cells |
intermittent claudication |
2 |
Pluristem Therapeutics (Israel) |
Cardiovascular diseases |
2017-01-12
|
Lutathera® ([177]Lutetium-DOTA[0]-Tyr[3]-Octreotate) |
inoperable, progressive, somatostatin receptor positive, midgut carcinoid tumors |
3 |
Advanced Accelerator Applications (France) |
Cancer - Oncology |
2017-01-12
|
bimagrumab (BYM338) |
obese patients with type 2 diabetes |
2 |
Novartis (Switzerland) |
Metabolic diseases |
2017-01-12
|
|
picornavirus infections |
preclinical |
Haplogen (Austria) |
Infectious diseases |
2017-01-11
|
SFX-01 |
aneurysmal subarachnoid haemorrhage |
2 |
Evgen Pharma (UK) |
Cerebrovascular diseases |
2017-01-11
|
TG-1101 (ublituximab) |
multiple sclerosis |
2 |
TG Therapeutics (USA - NY) |
Autoimmune diseases - Neurodegenerative diseases |
2017-01-11
|
ALX-0171 |
respiratory syncytial virus lower respiratory tract infection |
2 |
Ablynx (Belgium) |
Infectious diseases - Respiratory diseases |
2017-01-10
|
CPI-444 |
solid tumors |
1-1b |
Corvus Pharmaceuticals (USA - CA) |
Cancer - Oncology |
2017-01-10
|
Parsabiv™ (etelcalcetide - AMG 416) |
secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) on hemodialysis |
3 |
Amgen (USA - CA) |
Kidney diseases - Metabolic diseases - Renal diseases |
2017-01-10
|
RHB-105 (amoxicillin, rifabutin and omeprazole) |
Helictobacter pylori infection |
1 |
RedHill Biopharma (Israel) |
Infectious diseases |
2017-01-10
|
CHS-1420 (biosimilar version of Humira® (adalimumab)) |
plaque psoriasis |
3 |
Coherus Biosciences (USA - CA) |
Autoimmune diseases - Dermatological diseases |
2017-01-10
|
PLX-PAD cells |
critical limb ischemia |
3 |
Pluristem Therapeutics (Israel) |
Cardiovascular diseases |
2017-01-10
|
AUT00206 |
schizophrenia |
1a |
Autifony Therapeutics (UK) |
CNS diseases - Mental diseases |
2017-01-10
|
AUT00206 |
schizophrenia |
1b |
Autifony Therapeutics (UK) |
CNS diseases - Mental diseases |
2017-01-10
|
Debio 1450 |
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) due to Staphylococci |
2 |
Debiopharm (Switzerland) |
Infectious diseases |
2017-01-09
|
voretigene neparvovec - SPK-RPE65 |
inherited retinal disease (IRD) caused by biallelic RPE65 mutations. |
1 |
Spark Therapeutics (USA - PA) |
Rare diseases - Genetic diseases - Ophtalmological diseases |
2017-01-09
|
RG6016 |
small cell lung cancer |
1 |
Roche (Switzerland) |
Cancer - Oncology |